Cerus (CERS) Net Equity Issued and Repurchased (2010 - 2025)
Cerus (CERS) reported Net Equity Issued and Repurchased of $52000.0 for Q3 2025, up 223.81% on a YoY basis from $16058.8 in Q3 2024, and up 267.74% sequentially from -$31000.0 in Q2 2025.
Cerus (CERS) Net Equity Issued and Repurchased (2010 - 2025) Analysis & Trends
Cerus (CERS) has 16 years of Net Equity Issued and Repurchased data on file, last reported at $52000.0 in Q3 2025.
- For the quarter ending Q3 2025, Net Equity Issued and Repurchased rose 223.81% year-over-year to $52000.0; the trailing twelve-month figure through Mar 2026 stood at $21000.0 (up 110.88% YoY), and the FY2025 full-year result was -$35000.0, up 74.45% from the prior year.
- Net Equity Issued and Repurchased improved to $52000.0 in Q3 2025, from -$31000.0 in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $3.1 million in Q4 2021 to a low of -$72000.0 in Q1 2023.
- A 5-year average of $206000.0 and a median of -$42000.0 in 2024 frame the typical range for Net Equity Issued and Repurchased.
- Across the five-year window, Net Equity Issued and Repurchased soared 23961.54% in 2021 and plunged 102.0% in 2022, its largest moves.
- Tracing CERS's Net Equity Issued and Repurchased over 5 years: stood at $3.1 million in 2021, then sank by 102.0% to -$62000.0 in 2022, then soared by 38.71% to -$38000.0 in 2023, then gained by 21.05% to -$30000.0 in 2024, then surged by 273.33% to $52000.0 in 2025.
- Business Quant data shows CERS's Net Equity Issued and Repurchased at $52000.0 in Q3 2025, -$31000.0 in Q2 2025, and -$56000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | - |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | - |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 97.00 Mn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 12.70 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | - |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | - |
| 10 | Cerus | 600.87 Mn | 520.44 Mn | 27.89 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 52,000.00 |
| Sep 30, 2025 | 52,000.00 |
| Jun 30, 2025 | -31,000.00 |
| Jun 30, 2025 | -31,000.00 |
| Mar 31, 2025 | -56,000.00 |
| Mar 31, 2025 | -56,000.00 |
| Dec 31, 2024 | -30,000.00 |
| Dec 31, 2024 | -30,000.00 |
| Sep 30, 2024 | -42,000.00 |
| Sep 30, 2024 | -42,000.00 |
| Jun 30, 2024 | -65,000.00 |
| Jun 30, 2024 | -65,000.00 |
| Dec 31, 2023 | -38,000.00 |
| Dec 31, 2023 | -38,000.00 |
| Jun 30, 2023 | -65,000.00 |
| Jun 30, 2023 | -65,000.00 |
| Mar 31, 2023 | -72,000.00 |
| Mar 31, 2023 | -72,000.00 |
| Dec 31, 2022 | -62,000.00 |
| Dec 31, 2022 | -62,000.00 |